TTR and neuropathy: From baseline to Week 65, the modified body mass index was maintained with eplontersen compared to a marked reduction (worsening) for placebo.<h4>Conclusions</h4>Findings were suggestive of consistent benefits in reducing neuropathy impairment and improving QoL with eplontersen versus historical placebo, across TTR variants.<h4>Trial registration</h4>ClinicalTrials.gov: NCT04136184, NCT01737398.